Literature DB >> 35084622

Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.

Changchun Li1, Ruiqing Li2, Xingchi Hu3, Guangjun Zhou3, Guoqing Jiang4.   

Abstract

INTRODUCTION: Breast cancer metastasis is the main cause of cancer-related death in women worldwide. Current therapies have remarkably improved the prognosis of breast cancer patients but still fail to manage metastatic breast cancer. Here, the present study was set to explore the role of microRNA (miR)-660 from tumor-associated macrophages (TAMs) in breast cancer, particularly in metastasis.
MATERIALS AND METHODS: We collected breast cancer tissues and isolated their polarized macrophages as well as extracellular vesicles (EVs), in which we measured the expression of miR-660, Kelch-like Protein 21 (KLHL21), and nuclear factor-κB (NF-κB) p65. Breast cancer cells were transfected with miR-660 mimic, miR-660 inhibitor, and sh-KLHL21 and then the cells were co-cultured with EVs or TAMs followed by detection of invasion and migration. Finally, mouse model of breast cancer was established to detect the effect of miR-660 or KLHL21 on metastasis by measuring the lymph node metastasis (LNM) foci in femur and lung.
RESULTS: KLHL21 was poorly expressed, whereas miR-660 was highly expressed in breast cancer tissues and cells. Of note, low KLHL21 expression or high miR-660 expression was related to poor overall survival. EVs-contained miR-660 was identified to bind to KLHL21, reducing the binding between KLHL21 and inhibitor kappa B kinase β (IKKβ) to activate the NF-κB p65 signaling pathway. Interestingly, EV-loaded miR-660 from TAMs could be internalized by breast cancer cells. Moreover, silencing of KLHL21 increased the number of lung LNM foci in vivo, while EVs-contained miR-660 promoted cancerous cell invasion and migration. DISCUSSION: Taken altogether, our work shows that TAMs-EVs-shuttled miR-660 promotes breast cancer progression through KLHL21-mediated IKKβ/NF-κB p65 axis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; Extracellular vesicles; Metastasis; NF-κB p65; Tumor-associated macrophages; microRNA-660

Mesh:

Substances:

Year:  2022        PMID: 35084622     DOI: 10.1007/s10549-021-06433-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  43 in total

Review 1.  Perivascular macrophages in health and disease.

Authors:  Antonio Lapenna; Michele De Palma; Claire E Lewis
Journal:  Nat Rev Immunol       Date:  2018-11       Impact factor: 53.106

Review 2.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

Review 3.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy.

Authors:  Yoshihiro Komohara; Yukio Fujiwara; Koji Ohnishi; Motohiro Takeya
Journal:  Adv Drug Deliv Rev       Date:  2015-11-24       Impact factor: 15.470

Review 4.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

Review 5.  Breast cancer.

Authors:  Nadia Harbeck; Michael Gnant
Journal:  Lancet       Date:  2016-11-17       Impact factor: 79.321

Review 6.  MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages.

Authors:  Chong Chen; Jia-Ming Liu; Yun-Ping Luo
Journal:  J Zhejiang Univ Sci B       Date:  2020 Jan.       Impact factor: 3.066

Review 7.  Tumor-associated macrophages in breast cancer: Innocent bystander or important player?

Authors:  Si-Qi Qiu; Stijn J H Waaijer; Mieke C Zwager; Elisabeth G E de Vries; Bert van der Vegt; Carolien P Schröder
Journal:  Cancer Treat Rev       Date:  2018-08-28       Impact factor: 12.111

8.  Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.

Authors:  Luca Cassetta; Stamatina Fragkogianni; Andrew H Sims; Agnieszka Swierczak; Lesley M Forrester; Hui Zhang; Daniel Y H Soong; Tiziana Cotechini; Pavana Anur; Elaine Y Lin; Antonella Fidanza; Martha Lopez-Yrigoyen; Michael R Millar; Alexandra Urman; Zhichao Ai; Paul T Spellman; E Shelley Hwang; J Michael Dixon; Lisa Wiechmann; Lisa M Coussens; Harriet O Smith; Jeffrey W Pollard
Journal:  Cancer Cell       Date:  2019-03-28       Impact factor: 31.743

Review 9.  Progress in adjuvant systemic therapy for breast cancer.

Authors:  Noam F Pondé; Dimitrios Zardavas; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

10.  Integrated miRNA and mRNA profiling of tumor-educated macrophages identifies prognostic subgroups in estrogen receptor-positive breast cancer.

Authors:  Annalen Bleckmann; Andreas Leha; Stephan Artmann; Kerstin Menck; Gabriela Salinas-Riester; Claudia Binder; Tobias Pukrop; Tim Beissbarth; Florian Klemm
Journal:  Mol Oncol       Date:  2014-08-16       Impact factor: 6.603

View more
  1 in total

Review 1.  Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy.

Authors:  Shahzad Nawaz Syed; Bernhard Brüne
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.